Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Co.'s key product candidate, DSG3-CAART, is being evaluated for the treatment of mucosal pemphigus vulgaris (mPV), a subtype of PV that affects mucosal surfaces. Co.'s key preclinical product candidate, MuSK-CAART, is designed to treat a subset of patients with myasthenia gravis. Co. is also developing other product candidates in discovery-stage or preclinical development for the treatment of mucocutaneous PV, and Hemophilia A with Factor VIII, or FVIII, alloantibodies in addition to three undisclosed targets. The CABA stock yearly return is shown above.
The yearly return on the CABA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CABA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|